CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled
Drug / intervention
Capecitabinedrug
Likely dose
Capecitabine 1650 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01152710
NCT01152710Phase 2Completed
CompareCT.gov

Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer

Institute of Oncology Ljubljana·interventional·Posted Jun 29, 2010·Updated Jun 29, 2010

In Brief

A Phase 2 clinical trial evaluating Capecitabine for Resectable Rectal Cancer Clinical Stage II and III. Completed, enrolled 57 participants across 1 site.

Detailed Summary

A Phase II study aimed to evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced resectable rectal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsResectable Rectal Cancer Clinical Stage II and III
CountriesSlovenia
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 29, 2010
Enrollment StartJun 1, 2004
Primary CompletionMar 1, 2006
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.0 years ago

Interventions

Capecitabinedrug

Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends